Copy
See below for a daily digest of the latest Huntington's Disease news!

New Research Data Network Aims to Advance Discovery of Huntington’s Treatment

Jul 20, 2017 12:37 pm | Magdalena Kegel

 

Huntington's disease data networkResearchers have created the first freely available data network — called HDNetDB — that aims to advance research into Huntington’s disease and speed up drug discovery for the incurable condition. The approach, described in an article in the journal Scientific Reports, particularly focuses on the complex molecular workings that characterize the disease. The network is […]

The post New Research Data Network Aims to Advance Discovery of Huntington’s Treatment appeared first on Huntington's Disease News.

Read More
share on Twitter Like New Research Data Network Aims to Advance Discovery of Huntington’s Treatment on Facebook

Wave Life Sciences to Start Trials of Two Therapies That Target Huntington’s Mutations

Jul 18, 2017 04:37 am | Joana Fernandes, PhD

 

Mutations therapiesWave Life Sciences will start two Phase 1b/2a clinical trials to investigate the safety and tolerability of its products WVE-120101 and WVE-120102 in Huntington’s disease patients. The trials will also look at the therapies’ effectiveness. “Wave’s PRECISION-HD program is the first to target the underlying cause of Huntington’s disease with an allele-specific approach,” Dr. Michael […]

The post Wave Life Sciences to Start Trials of Two Therapies That Target Huntington’s Mutations appeared first on Huntington's Disease News.

Read More
share on Twitter Like Wave Life Sciences to Start Trials of Two Therapies That Target Huntington’s Mutations on Facebook

Recent Posts

People with Chorea Can Switch from Xenazine To Austedo Safely, Phase 3 Clinical Trial Shows
Metabolic Changes in Certain Brain Regions May Be Associated with Huntington’s Motor Symptoms
MSH3 Gene Mutations May Be Involved in Huntington’s Disease Progression, Study Finds
Mitoconix Bio Obtains $20 Million To Continue Developing Huntington’s Therapy MTC-1203
Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease

Copyright © 2017 BioNews Inc., All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences